An observational study in Venous Thromboembolic Disease, Post Thrombotic Syndrome and Chronic Thromboembolic Pulmonary Hypertension, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Status unknown at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH) respectively. Our aim of the study is to compare the long term outcomes along with the quality of life assessment of VTE in a group treated with heparin+VKA versus a group treated with heparin+edoxaban in the acute setting.
67 studies on the registry are indexed under Postthrombotic Syndrome; 22 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 294 across 22 observational studies indexed under Postthrombotic Syndrome.
Browse Postthrombotic Syndrome studies →Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 185 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who were included in the HOKUSAI VTE trial for treatment of their DVT or PE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
Other: Observation
Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised.
Other: Observation
No intervention
Post thrombotic syndrome (PTS)
PTS according to Villalta
Time frame: up to 10 years
Chronic thromboembolic pulmonary hypertension (CTEPH)
according to clinical and objective criteria
Time frame: up to 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →